RecruitingPhase 4

Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

Pakistan800 participantsStarted 2025-10-30

Plain-language summary

The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients of any gender
✓. Patients aged between 18-80 years
✓. Patients having HbA1c 8 % or above
✓. Patients diagnosed with type II diabetes (more than at least 06 months)
✓. Patients already on at least 02 or more anti-diabetic agents
✓. Patients not allergic to empagliflozin, linagliptin, or metformin

Exclusion criteria

✕. Patients with age less than 18
✕. Patients with Type-I diabetes
✕. Patients having diabetes for less than 06 months
✕. Patients on GLP-1 and GIP
✕. Patients who are pregnant or lactating females
✕. Patients with decompensated chronic liver disease (DCLD)
✕. Patients with eGFR less than 30 ml
✕. Patients with end-stage heart failure (NYHA Class 4)

What they're measuring

Changes in HbA1c levels

Timeframe: 03 months, 06 months

Trial details

NCT IDNCT06862739

SponsorNabiqasim Industries (Pvt) Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-04-30

View on ClinicalTrials.gov More Diabetes Mellitus trials